Regulation of Monoamine Oxidase in Parkinson Disease

Parkin regulated protein turnover.

In an earlier blog post I linked to an article about the potential role of dopamine metabolism and oxidative stress in Parkinson disease. Now the research group of Jian Feng reports that the protein Parkin regulates the expression of monoamine oxidase in human dopaminergic neurons (Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells).

As early as 2003, experiments in mice linked low levels of Parkin to increased metabolism of dopamine by monoamine oxidase (1). One of the existing treatments for Parkinson Disease is inhibition of monoamine oxidase (see: “The role of rasagiline in the treatment of Parkinson’s disease“).

Feng’s group started with skin cells from human patients with mutated Parkin genes. They made pluripotent stem cells from the skin cells and then induced the stem cells to differentiate into dopaminergic neurons for use in their studies of the role of Parkin in human neurons.

Parkinson Disease patients with defective Parkin genes might particularly benefit from treatment with monoamine oxidase inhibitors.

Image source: European Iron Club.

Advertisements

About johnwschmidt

Exploring medical physiology.
This entry was posted in L-DOPA, Parkinson disease, proteolysis and tagged , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s